Collaboration opportunity | Licensing opportunity
Verona Pharma plc, a drug discovery company that is quoted on the Alternative Investment Market in London, announced the final results of a Phase I/IIa trial of RPL554 in the treatment of asthma, and said it is looking for a commercialisation partner.
The study was designed to ascertain whether a safe dose of RPL554, given by inhalation to a group of clinically stable mildly asthmatic patients that were not on maintenance anti-asthma therapy, produced bronchodilation relaxation of airways and broncho- protection (protection against the airway stimulant methacholine).
In a separate group of asymptomatic patients with allergic rhinitis who were not on maintenance therapy, the effects of RPL554 on the inflammatory cellular responses to a nasal allergen challenge were tested.
RPL554 showed clear clinical benefits in the proof of concept trial in patients with asthma and allergic rhinitis, while showing a good safety profile
Verona Pharma is now looking to partner or license RPL554
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
